Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 2Prostatic Neoplasms 2Carcinoma, Transitional Cell 2Urologic Neoplasms 1Squamous Cell Lung Cancer 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 6Trastuzumab 4Carboplatin 3pembrolizumab 2Pemetrexed 2Paclitaxel 2Cisplatin 2vinflunine 1tucatinib 1relatlimab 1palbociclib 1niraparib 1motexafin gadolinium 1montanide ISA 51 1flt3 ligand protein 1enfortumab vedotin 1cabozantinib 1atezolizumab 1apatorsen 1abemaciclib 1Zoledronic Acid 1Urinary Diversion 1Therapeutics 1Thalidomide 1Sunitinib 1Radiosurgery 1Nivolumab 1Mitomycin 1MART-1 Antigen 1Immunoglobulins, Intravenous 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Urologic Neoplasms × apatorsen × Clear all
NCT01454089 2016-10-07

A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

Achieve Life Sciences

Phase 2 Completed
183 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡